Sirtex Medical Inc. Reports 23.7 Percent Dose Sales Growth of SIR-Spheres® microspheres in Second Quarter
14 January 2014 - 2:00AM
Business Wire
Globally Sirtex Achieves 38 Consecutive
Quarters of Dose Sales Growth
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited
(ASX:SRX), a leading manufacturer of targeted, innovative liver
cancer therapies, recently announced that second quarter dose sales
of SIR-Spheres® microspheres grew 23.7 percent in the Americas
region compared to the previous corresponding period for the
quarter ending December 31, 2013.
“The Americas team continues to execute our strategic plan to
expand the use of SIR-Spheres microspheres in both North and South
America and as a result experienced outstanding dose sales growth
in the second quarter,” said Mike Mangano, president of Sirtex
Medical Inc. “During the remainder of this fiscal year we will
focus our efforts on educating physician communities about the
latest data that continues to demonstrate the therapy’s safety and
efficacy. We look forward to the results of the landmark SIRFLOX
study, which completed enrollment in April 2013 and is intended to
further illustrate SIR-Spheres microspheres’ role as an earlier
standard of care for metastatic colorectal cancer patients.”
Dose sales in all regions rose a combined 18.7 percent during
the period. Europe, Middle East and Africa (EMEA) achieved dose
sales growth of 5.9 percent and Asia Pacific grew 18.2 percent.
Full mid-year financial results will be released later in the
quarter.
For more information visit www.Sirtex.com or find the latest
updates on the SIR-Spheres microspheres Facebook page
(www.Facebook.com/SIRSpheresmicrospheres).
About Selective Internal Radiation Therapy using SIR-Spheres
microspheres
Selective Internal Radiation Therapy (SIRT), also known as
radioembolization, is a proven technology for inoperable liver
cancer that delivers doses of radiation directly to the site of
tumors. In a minimally invasive treatment, millions of radioactive
SIR-Spheres microspheres are infused via a catheter into the liver
where they selectively target liver tumors with a dose of internal
radiation up to 40 times higher than conventional radiotherapy,
while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic
colorectal cancer treated with SIR-Spheres microspheres have
response rates higher than with other forms of treatment, resulting
in increased life expectancy, greater periods without tumor
activity and improved quality of life. SIRT has been found to
shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the
United States of America (FDA PMA approval), the European Union (CE
Mark), Argentina (ANMAT), New Zealand, Switzerland, Turkey, and
several other countries in Asia such as India, Korea, Singapore,
and Hong Kong. Additionally, SIR-Spheres microspheres are supplied
in countries such as Malaysia, Thailand, Taiwan, and Israel.
Available at more than 700 treatment centers, over 35,000 doses of
SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty
Ltd.
For Sirtex Medical Inc.Elizabeth Romero,
919-457-0749elizabeth.romero@fleishman.com
Sierra Rutile (ASX:SRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sierra Rutile (ASX:SRX)
Historical Stock Chart
From Nov 2023 to Nov 2024
